ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pimurutamab

Also written as “HLX07”, “HLX43+HLX07” and “HLX43 DOSE 2 + HLX10 + HLX07”.

In Fosun Pharma’s pipeline, pimurutamab. Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colonic Neoplasms · Nasopharyngeal Carcinoma · Squamous Cell Carcinoma of Head and Neck · Carcinoma, Adenosquamous, led by 2 companies.

Drug pageHLX07: every studyAll 18 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jan 4, 202617 company-led studies, 8 open or runningNext primary completion: Jul 28, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fosun Pharmaits history only168 open or runningphase 3since Jan 4, 2026Jun 11, 2018Jul 28, 2027phase 2 · NCT07358585
Henlix10 open or runningphase 1since Dec 27, 2015Dec 27, 2015none ahead
  • Named in Fosun Pharma’s own pipeline as HLX07 (pimurutamab), phase 2, as of Sep 21, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Henlix only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 27, 2015First study: phase 1 study in Neoplasm MetastasisFirst studyNCT02648490 · 19 enrolled · United States, Taiwan
  2. Dec 9, 2019Named pimurutamabINNProposed as its International Nonproprietary Name in WHO's List 122

TargetBeta

“pimurutamab”the company's pipeline, read by Claude · source
“A glycoengineered humanized version of the monoclonal antibody of cetuximab, with potential antineoplastic activity. Upon intravenous administration, pimurutamab selectively targets and binds to the extracellular domain of the epidermal growth factor receptor (EGFR), thereby preventing the activa…”NCIt, read by Claude
“Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
befotertinibruleBetta Pharmaceuticalsphase 36
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
zipalertinibruleOtsukaphase 34

Studies

The one study Henlix leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02648490Neoplasm Metastasis · United States, Taiwan1CompletedJun 28, 201919

How it is read

Names in the registry

  • “HLX07”, 12 entries
  • “HLX43+HLX07”, 1 entry
  • “HLX43 DOSE 2 + HLX10 + HLX07”, 1 entry
  • “HLX43 DOSE 3 + HLX10 + HLX07”, 1 entry
  • “HLX43 dose 1 + HLX07”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.